AKT1 and lung cancer: The increased expression and activation of c‐MET in response to EGFR TKIs (Engelman et al., 2007) and cytotoxic anticancer agent (Ozasa et al., 2014) contribute to drug resistance in lung cancer cells through compensatory enhancing of Akt signaling.